Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10–60 Years Age Group: a Follow-up Report Based on Phase III Clinical Trial

• DOI: 10.20944/preprints202408.1729.v1
• Publication Date: 2024-08-26T01:00:31Z
• Authors: Yunpeng Wang; Zhiang Wu; Jia Li; Shouchun Cao; Leitai Shi; Danhua Zhao; Zhaojun Mo; Haiyan Liang; Xiaohong Wu
• Keywords: Persistence (discontinuity); Rabies vaccine

We evaluated the immunogenicity persistence of different immunization regimens freeze-dried human rabies vaccine (Vero cells) in 10–60 years age group Chinese population. Based on phase III clinical trials Vero cells, participants who completed full course were continuously enrolled four-dose trial, five-dose, and five-dose control groups. Venous blood samples collected 12 months after completion for virus-neutralizing antibody (RVNA) testing, antibody-positive rate geometric mean concentration (GMC) calculated. Analysis variance was used to compare three The groups included 200, 186, 214 participants, respectively. Twelve immunization, overall RVNA-positive rates 97.00%, 93.55%, 94.86% control, trial groups, post-immunization RVNA GMCs values 2.50, 2.05, 2.04 IU/mL, respectively, with no statistically significant differences between them. remained high, demonstrating satisfactory both regimens.